Seminar: 'Meet the Experts' on the BENEFITS OF Medicinal Cannabis
Venue: Kehilat Nitzan, 36-40 Hawthorn Road, Caulfield North & Online
Sunday September 11 7:00pm – 8:30pm
Special Guest. Dr Igal Louria-Hayon: Rambam Medical Cannabis Research and Innovation Centre
The Medical Cannabis Research and Innovation Centre studies the role of cannabinoids under various disease conditions. The centre focuses on the specific biochemical interactions that trigger the physiological effects of plant-derived cannabinoids. This knowledge contributes to the infrastructure of cannabis-based treatments approved by the health authorities in Israel and worldwide.
CHAIRED BY PROFESSOR JONATHAN CEBON: IMMEDIATE PAST MEDICAL DIRECTOR, OLIVIA NEWTON JOHN CANCER WELLNESS & RESEARCH CENTRE. JONATHAN HAS A LONGSTANDING INTEREST IN CANCER CARE AND IMMUNOLOGY. AS MEDICAL DIRECTOR AT ONJCWRC HE COLLABORATED WITH OLIVIA NEWTON-JOHN TO DEVELOP A CLINICAL RESEARCH PROGRAMME FOR EVALUATING MEDICAL CANNABIS FOR THE MANAGEMENT OF PATIENTS WITH CANCER
PanelLists:
Rhys Cohen: Senior Corporate Communications Manager at Cann Group. Rhys has delivered consulting projects to most of Australia’s leading cannabis companies and is currently the Senior Corporate Communications Manager at Cann Group (ASX:CAN). He sits on the non-executive advisory board of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney and was previously editor-at-large at Cannabiz, Australia's leading B2B industry publication.
Peter Crock: Peter is Chairman of Medicinal Cannabis Industry Australia (MCIA) which is Australia’s peak medicinal cannabis industry organisation for licence holders and CEO of Cann Group Limited. Cann Group is taking a leading role in establishing cultivation and research capabilities within the new regulatory framework in Australia and was the first company to be issued licences and permits to cultivate medicinal cannabis by the Office of Drug Control.
Tommy Huppert, CEO of Cannatrek Limited, an Australian company specialising in the research, cultivation, manufacturing and delivery of medical cannabis. Backed by medicinal licenses, Cannatrek manages the entire product lifecycle of plant based therapies from growth and processing to distribution and sales. Its ecosystem of suppliers, doctors, pharmacists and patients is connected by a digital platform which deliversinformation on plant based therapies to eligible patients.
extra speaker!
Integrative GP and Medical Writer Associate Professor Vicki Kotsirilos AM is a respected Specialist GP with over 35 years of clinical experience. IN MAY 2019 she became Australia’s first authorised GP prescriber of medicinal cannabis.
The first in-depth study by the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics of Australia’s medicinal cannabis program, co-authored by Professor Kotsirilos, which began in 2016, shows the drug is being increasingly prescribed for many different conditions.
Venue: Kehilat Nitzan, 36-40 Hawthorn Road, Caulfield North & Online
Sunday September 11 7:00pm – 8:30pm
Special Guest. Dr Igal Louria-Hayon: Rambam Medical Cannabis Research and Innovation Centre
The Medical Cannabis Research and Innovation Centre studies the role of cannabinoids under various disease conditions. The centre focuses on the specific biochemical interactions that trigger the physiological effects of plant-derived cannabinoids. This knowledge contributes to the infrastructure of cannabis-based treatments approved by the health authorities in Israel and worldwide.
CHAIRED BY PROFESSOR JONATHAN CEBON: IMMEDIATE PAST MEDICAL DIRECTOR, OLIVIA NEWTON JOHN CANCER WELLNESS & RESEARCH CENTRE. JONATHAN HAS A LONGSTANDING INTEREST IN CANCER CARE AND IMMUNOLOGY. AS MEDICAL DIRECTOR AT ONJCWRC HE COLLABORATED WITH OLIVIA NEWTON-JOHN TO DEVELOP A CLINICAL RESEARCH PROGRAMME FOR EVALUATING MEDICAL CANNABIS FOR THE MANAGEMENT OF PATIENTS WITH CANCER
PanelLists:
Rhys Cohen: Senior Corporate Communications Manager at Cann Group. Rhys has delivered consulting projects to most of Australia’s leading cannabis companies and is currently the Senior Corporate Communications Manager at Cann Group (ASX:CAN). He sits on the non-executive advisory board of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney and was previously editor-at-large at Cannabiz, Australia's leading B2B industry publication.
Peter Crock: Peter is Chairman of Medicinal Cannabis Industry Australia (MCIA) which is Australia’s peak medicinal cannabis industry organisation for licence holders and CEO of Cann Group Limited. Cann Group is taking a leading role in establishing cultivation and research capabilities within the new regulatory framework in Australia and was the first company to be issued licences and permits to cultivate medicinal cannabis by the Office of Drug Control.
Tommy Huppert, CEO of Cannatrek Limited, an Australian company specialising in the research, cultivation, manufacturing and delivery of medical cannabis. Backed by medicinal licenses, Cannatrek manages the entire product lifecycle of plant based therapies from growth and processing to distribution and sales. Its ecosystem of suppliers, doctors, pharmacists and patients is connected by a digital platform which deliversinformation on plant based therapies to eligible patients.
extra speaker!
Integrative GP and Medical Writer Associate Professor Vicki Kotsirilos AM is a respected Specialist GP with over 35 years of clinical experience. IN MAY 2019 she became Australia’s first authorised GP prescriber of medicinal cannabis.
The first in-depth study by the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics of Australia’s medicinal cannabis program, co-authored by Professor Kotsirilos, which began in 2016, shows the drug is being increasingly prescribed for many different conditions.